Schramm Vern Lee 4
4 · AzurRx BioPharma, Inc. · Filed Mar 13, 2020
Insider Transaction Report
Form 4
Schramm Vern Lee
Director
Transactions
- Award
Common Stock
2020-03-11$1.04/sh+8,414$8,751→ 90,498 total - Award
Common Stock
2020-03-11$0.60/sh+14,584$8,750→ 82,084 total
Footnotes (4)
- [F1]Shares issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending September 30, 2019.
- [F2]Based on the stock price at September 30, 2019, at which time cash compensation would have otherwise been paid for service on the Issuer's Board of Directors.
- [F3]Shares issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending December 31, 2019.
- [F4]Based on the stock price at December 31, 2019, at which time cash compensation would have otherwise been paid for service on the Issuer's Board of Directors.